RF EMerge

A Resource for Innovators

The United States Patent and Trademark Office (USPTO) announced today the finalized fee increases taking effect on January 19, 2025. While applicants can still expect significant increases in certain areas, some proposed fee increases were not implemented following pushback from public commentators. One notable example relates to terminal disclaimers. The USPTO had proposed a tiered

The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is no exception.

AI-driven platforms have become increasingly useful to biotech innovators in many areas including in discovering and developing drugs. For example, a 2022 article by McKinsey & Company estimated that nearly 270 companies have

The Corporate Transparency Act (CTA) went into effect on January 1, 2024, and will impact millions of U.S. businesses by imposing requirements to file corporate transparency reports with beneficial ownership information (“BOI”) before January 1, 2025.  Here, we summarize some key points and remind business owners to comply with these new requirements as soon as possible

As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage, and new market entrants must take careful consideration of this landscape and develop a strategy to best position their businesses in this evolving space. This post provides an analytical framework for advanced IP considerations to

The Unted States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence (AI), opening a written comment window to respond with a deadline of September 16, 2024. The guidance was brought about by an October 2023 Executive Order on the “Safe, Secure, and Trustworthy Development and

Heading into 2025, patent applicants should prepare for significant fee increases at the United States Patent and Trademark Office (USPTO). These fee increases can significantly impact patent applicant behavior, leading prudent applicants to evaluate and adjust their patent protection strategies.  Pharmaceutical and biotechnology companies in particular should plan and budget for new and drastically increased

BASE Air is a company at the leading edge of safety in the heavy vehicle industry. Founded in 2005 by Matthew Vaughan in Australia, the company focuses on Balance and Safety Enhancement (BASE) for heavy-duty vehicle stability. BASE Air’s technology is a pressure-control system capable of integrating into a vehicle’s existing air suspension, or available

In a long-awaited milestone in the gene therapy space, the Food and Drug Administration (FDA) approved two gene therapies to cure sickle cell disease (SCD).  Soon thereafter these approvals, a key licensing agreement was announced between Vertex and Editas for Cas9 gene editing technology.

Gene therapy is a new type of treatment with the potential